---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045904"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:31:24.184695+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics Q3 revenue up 17% to $3.9M; operating loss down 27%; FDA clearance for pediatric OSA

## Summary
- Q3 2024 revenue $3.9M (+17% YoY); gross margin improved to 60% from 53%.
- Operating loss decreased $1M (27%) YoY; operating expenses down 8% — ninth consecutive quarter of reduction.
- Cash and equivalents $6.3M, stockholders' equity $7.7M; raised $4.3M via registered direct equity offering in Sept.
- First FDA 510(k) clearance for treating moderate-to-severe OSA in children 6-17; AMA CPT codes for Vivos devices effective Jan 1, 2025.
- Over 47,000 patients treated globally; new marketing model expanding to two more Colorado locations by early 2025.

## SEC filing metadata
- accession: 0001493152-24-045904
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224045904/0001493152-24-045904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224045904/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045904
- JSON: https://secwatch.observer/filing/0001493152-24-045904.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.